Development of Orally Ingestible IgA Antibody Drugs to Maintain Symbiosis Between Humans and Microorganisms

Adv Exp Med Biol. 2024;1444:165-176. doi: 10.1007/978-981-99-9781-7_11.ABSTRACTIn recent years, dysbiosis, abnormalities in the gut microbiota, has been reported to be associated with the development of many diseases, and improving the gut microbiota is important for health maintenance. It has been shown that the host recognizes and regulates intestinal bacteria by means of IgA antibodies secreted into the gut, but the precise nature of the commensal gut bacteria recognized by each IgA antibody is unclear. We have cloned monoclonal IgA antibodies from mouse intestinal IgA-producing cells and are searching for bacterial molecules recognized by each IgA clone. Although the interaction of IgA antibodies with intestinal bacteria is still largely unknown and requires further basic research, we discuss the potential use of orally ingestible IgA antibodies as agents to improve intestinal microbiota.PMID:38467979 | DOI:10.1007/978-981-99-9781-7_11

Source: Advances in Experimental Medicine and Biology - March 12, 2024 Category: Research Authors: Reiko Shinkura Source Type: research